Mobile devices and standards that support interoperability stand out in the shadowy world of cyber intrusions. They allow access to patient files, the making of information requests, the placing of exam orders from anywhere at any time. Those devices may be smartphones or tablets — each with varying levels of security. 

Proton International announced the successful financing of a new state-of-the-art radiation therapy center and a pioneering approach to proton center financing provided and coordinated by Loop Capital.

Seno Medical Instruments Inc. recently announced that is Imagio opto-acoustic (OA/US) breast imaging system results correlate with the histopathological findings of benign and malignant breast masses. These data were highlighted during an oral presentation at the American Roentgen Ray Society (ARRA) Annual Meeting, May 1-5 in New Orleans.

May 16, 2017 — Adept Medical announced the launch of the IR Platform, designed as an over-patient work surface for vascular and interventional radiology. The platform provides clinical benefits to the current practice of laying procedural equipment over the patient’s legs by offering a stable, radiolucent, height- and length-appropriate solution for femoral artery access procedures. It offers a stable solution for catheter/guide wire manipulation, with a large work area for equipment.

Moffitt Cancer Center Radiation Oncology Conference

A new study of high school football players adds to mounting evidence that the Q-Collar may help reduce brain injury from sports-related head impacts.

Soundwaves LLC recently announced the diversification of its portable ultrasound services beyond obstetrics and gynecology to other medical disciplines, including cardiology, and the expansion of its operations from South Florida to the Mid-Atlantic.

Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the FALCON clinical study of fluciclovine (18F) PET/CT imaging, based on successful results of a pre-planned interim analysis. The FALCON trial, announced in March 2016, is a U.K.-based, open-label study (NCT02578940) to evaluate the clinical impact of fluciclovine (18F) positron emission tomography/computed tomography (PET/CT) imaging on patient management decisions in men with biochemically recurrent prostate cancer.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now